Microneedle-based Rabies Vaccination: A Promising Approach Toward the WHO “Zero by ۳۰” Target

سال انتشار: 1405
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 178

فایل این مقاله در 12 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_ARCHRAZI-81-1_022

تاریخ نمایه سازی: 21 اردیبهشت 1405

چکیده مقاله:

Introduction: Rabies remains a fatal zoonotic disease causing tens of thousands of deaths annually, predominantly in resource-limited countries, where intramuscular (IM) vaccines are limited by cost, cold-chain needs, and the need for skilled administration. Achieving the World Health Organization’s “Zero by ۳۰” target necessitates innovative, scalable, and cost-effective vaccine delivery approaches. In this study, we developed dissolving microneedle (MN) patches (dMNPs) loaded with rabies vaccine using hyaluronic acid (HA) and polyvinylpyrrolidone (PVP) as biocompatible and biodegradable polymers. Materials & Methods: An aluminum master mold fabricated by CNC machining contained ۴۰۰ cubical-pyramidal MNs (۸۰۰ µm height, ۳۰۰×۳۰۰ µm base), while PDMS replicas enabled precise two-step centrifugal casting. Morphology, virion integrity, mechanical strength, and ex vivo skin penetration were evaluated. Bagg Albino/subline C (BALB/c) mice received two doses of vaccine-loaded microneedles, IM injection, or blank patches, and virus-neutralizing antibodies were measured. Results: MNs exhibited uniform geometry (۶۵۱.۲±۴.۳ μm height), high mechanical strength (۰.۴۰۳±۰.۰۰۶ N/needle), and reliable skin penetration (~۳۰۰ μm). Transmission electron microscopy confirmed that rabies virions retained their bullet-shaped morphology after encapsulation and storage. Rabies virus-neutralizing antibodies showed comparable titers four weeks post-booster: dMNP (۱ mg; geometric mean titers (GMTs): ۷.۶۷ IU/mL, ۹۵% CI, ۶.۸%, ۸.۶۴%) versus IM (۱۰ mg; GMT: ۶.۹۵ IU/mL, ۹۵% CI, ۶.۲%, ۷.۸%; P>۰.۰۵), both surpassing protective thresholds (≥۰.۵ IU/mL), while controls remained seronegative. Conclusion: Beyond achieving robust immune responses, these dMNPs provide dose-sparing, thermostability, self-administration, and sharps-free delivery—which enhance feasibility, acceptance, and scalability, aligning with the WHO’s “Zero by ۳۰” target. This platform offers translational potential for equitable rabies prophylaxis in resource-limited settings.

نویسندگان

Mehrnaz Hosseini Tehrani

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Reza Aramideh Khouy

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Atefeh Malek-Khatabi

Center for Advanced Biomaterials for Health Care (CABHC), Italian Institute of Technology, Napoli, Italy.

Mazda Rad-Malekshahi

Department of Pharmaceutical Biomaterials, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Atefeh Kachooei

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Maryam Shahali

Department of Viral Vaccines Production, Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran.

Babak Peirovi

Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Leila Mousavizadeh

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Hossein Keyvani

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Angila Ataei‐Pirkooh

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.